Veracyte, Inc. (VCYT) — SEC Filings
Veracyte, Inc. (VCYT) — 38 SEC filings. Latest: 10-Q (May 6, 2026). Includes 16 8-K, 9 SC 13G/A, 7 10-Q.
View Veracyte, Inc. on SEC EDGAR
Overview
Veracyte, Inc. (VCYT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Veracyte, Inc. (VCYT) reported a strong financial performance for the three and nine months ended September 30, 2025. Total revenue for the three months increased to $131.87 million from $115.86 million in the prior year, a 13.8% rise. For the nine-month period, total revenue grew to $376.51 million
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 2 bullish, 35 neutral, 1 mixed. The dominant filing sentiment for Veracyte, Inc. is neutral.
Filing Type Overview
Veracyte, Inc. (VCYT) has filed 7 10-Q, 16 8-K, 2 DEF 14A, 2 10-K, 1 SC 13G, 9 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of VCYT's 27 recent filings, 0 were flagged as high-risk, 7 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $131.87M |
| Net Income | $19.14M |
| EPS | $0.24 |
| Debt-to-Equity | 0.09 |
| Cash Position | $315.57M |
| Operating Margin | 69.2% |
| Total Assets | $1,367.79M |
| Total Debt | $110.12M |
Key Executives
- StapleyMember
- AndersonMember
- Dr. Richard W. Smith
- Ms. Jennifer L. Sim
- Bonnie Anderson
- Ron Apteker
- Dr. Richard M. Klausner
- Ms. Jennifer L. D. Smith
- Dr. Elna M. Johansson
Industry Context
Veracyte operates in the rapidly evolving molecular diagnostics market, focusing on oncology. The industry is characterized by innovation in biomarker discovery and the development of tests for early detection, prognosis, and treatment selection. Key trends include the shift towards personalized medicine and the increasing adoption of genomic and proteomic profiling. Competition comes from established diagnostic companies and emerging players in specialized areas like minimal residual disease detection.
Top Tags
amendment (6) · financial-reporting (5) · institutional-ownership (5) · financial-condition (4) · corporate-governance (4) · 10-Q (4) · financials (4) · operations (3) · sec-filing (3) · Veracyte (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue (Q3 2025) | $131.87M | Increased from $115.86M in Q3 2024, a 13.8% rise. |
| Total Revenue (YTD Sept 2025) | $376.51M | Increased from $327.13M in YTD Sept 2024, a 15.1% rise. |
| Net Income (Q3 2025) | $19.14M | Increased from $15.16M in Q3 2024, a 26.2% rise. |
| Net Income (YTD Sept 2025) | $25.20M | Increased from $19.03M in YTD Sept 2024, a 32.4% rise. |
| Cash and Cash Equivalents (Sept 30, 2025) | $315.57M | Increased from $239.09M at Dec 31, 2024. |
| Net Cash Provided by Operating Activities (YTD Sept 2025) | $83.72M | Increased from $50.57M in YTD Sept 2024. |
| Common Stock Shares Outstanding (Oct 31, 2025) | 79,049,173 | Reflects total shares outstanding. |
| Impairment of Assets (YTD Sept 2025) | $20.51M | Increased from $0.61M in YTD Sept 2024, indicating potential asset write-downs. |
| Total Revenue | $92.5M | Increased 15.6% in Q2 2025 from $80.0M in Q2 2024 |
| Net Loss | -$15.0M | Narrowed from -$20.0M in Q2 2024, showing improved financial performance |
| Revenue Growth | 15.6% | Year-over-year increase for Q2 2025, indicating strong market demand |
| Testing Revenue | $80.0M | Increased from $70.0M in Q2 2024, driving overall revenue growth |
| Product Revenue | $7.5M | Increased from $6.0M in Q2 2024, contributing to revenue diversification |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
| Reporting Period Start Date | 2025-01-01 | Indicates the start of the financial quarter being reported. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Veracyte, Inc. (VCYT)?
Veracyte, Inc. has 38 recent SEC filings from Jan 2024 to May 2026, including 16 8-K, 9 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VCYT filings?
Across 38 filings, the sentiment breakdown is: 2 bullish, 35 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Veracyte, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Veracyte, Inc. (VCYT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Veracyte, Inc.?
Key financial highlights from Veracyte, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VCYT?
The investment thesis for VCYT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Veracyte, Inc.?
Key executives identified across Veracyte, Inc.'s filings include StapleyMember, AndersonMember, Dr. Richard W. Smith, Ms. Jennifer L. Sim, Bonnie Anderson and 4 others.
What are the main risk factors for Veracyte, Inc. stock?
Of VCYT's 27 assessed filings, 0 were flagged high-risk, 7 medium-risk, and 20 low-risk.
What are recent predictions and forward guidance from Veracyte, Inc.?
Forward guidance and predictions for Veracyte, Inc. are extracted from SEC filings as they are enriched.